The Invisible Burden of Fatigue and Brain Fog in PBC

Key Takeaways:

• Fatigue is nearly universal in primary biliary cholangitis (PBC), and cognitive impairment is common. These symptoms are often the most life-limiting part of the disease and are not reliably improved by first-line therapy.
• Because fatigue and cognitive burden do not track alkaline phosphatase (ALP), bilirubin, or disease stage, they are invisible to the laboratory markers clinicians monitor – and often invisible socially, producing isolation.
• Eliciting and validating fatigue and cognitive burden directly is a low-cost, high-value part of the visit that is frequently missed.

For the clinician, a well-controlled case of primary biliary cholangitis (PBC) is often defined by the numbers: a falling alkaline phosphatase (ALP), a normal bilirubin, and a reassuring disease stage. Yet for many patients, the symptoms that most constrain daily life are precisely the ones those numbers do not capture.

In the 2026 In America survey of patients with PBC, 95 percent reported fatigue and 63 percent reported cognitive difficulty or brain fog, while only 5 percent reported no symptoms at all. One respondent described how "the staggering fatigue completely controls my life," adding, "I'm also depressed for the first time in my life."¹

The clinical question is not whether these symptoms are real, but how to recognize and address a burden that the monitored labs will never show.

The gap between labs and lived burden

The disconnect patients describe is supported by the evidence. In a UK-PBC cohort of 2,055 patients, the symptom domains that most impair quality of life were not associated with biochemical or disease severity. Advanced liver disease, measured by serum albumin, did not predict perceived quality-of-life impairment. Roughly a third of patients (34 percent) reported poor quality of life, and the single greatest predictor of that impairment was social dysfunction.²

This decoupling of prognosis from lived experience means a patient whose biochemistry has responded well to therapy may still be profoundly limited – a reality captured by the In America respondent who wrote, "Isolation. I look healthy, but [my] body says another thing. Tired of explaining to people why my body and mind are exhausted at the end of the day."¹

What the evidence shows about fatigue and stage

Fatigue is the most common symptom of PBC, and society guidance is explicit that there is not a good correlation between symptoms and disease stage. The PBC-40, the disease-specific quality-of-life instrument, devotes its largest domain to fatigue (11 items) and a separate domain to cognitive function (6 items). In its validation cohort, no domain score correlated with age, self-reported disease stage, time since diagnosis, or sex.^3,4

Critically, fatigue does not respond to the therapy that controls the biochemistry: Ursodeoxycholic acid (UDCA) does not improve it, and no pharmacotherapy has proven effective in controlled trials. What guidance does recommend is ruling out contributors that are treatable – hypothyroidism, anemia, depression, and sleep apnea – before attributing fatigue to PBC alone.^3,4

The recognition and elicitation gap

Cognitive symptoms compound the problem because patients are often reluctant to raise them. In the In America survey, brain fog was described as "embarrassing" and as a source of forgetfulness, the kind of symptom a patient may mask rather than report.¹

When 63 percent of respondents describe cognitive difficulty, yet the deficit is invisible on examination and absent from the chart, it is easily missed unless asked about. The same applies to the affective burden the data surface – 48 percent reported anxiety and 30 percent reported depression – which both worsen quality of life and, in the case of depression, must be distinguished from PBC fatigue rather than assumed to explain it.¹

Practical ways to surface and validate it

Because these symptoms will not appear in the labs, they have to be elicited verbally. Asking directly about fatigue severity, cognitive lapses, mood, and the social consequences – whether a patient has reduced or stopped working, as one respondent reported having had to do because of "fatigue, pain, brain fog, and nausea" – surfaces a burden the biochemistry conceals.⁴

Validating that the symptom is a recognized feature of PBC, rather than a personal failing or a sign that treatment is not working, addresses the isolation patients describe. Screening for and treating the reversible contributors that guidance flags, and acknowledging the limits of current therapy honestly, makes a brief conversation one of the highest-value parts of the visit.⁴